SCOTTSDALE, Ariz.

斯科茨代尔，亚利桑那州

,

，

May 14, 2026

2026年5月14日

/PRNewswire/ -- Advancing its commitment to high-growth innovation, Jetstream Venture Fund announced an investment in Wonderlab Bio, a pioneer in off-the-shelf cell therapies, further expanding everyday investors' access to elite venture opportunities. This strategic investment highlights Jetstream's commitment to backing transformative technologies across multiple sectors, positioning Wonderlab Bio's groundbreaking regenerative medicine alongside the fund's existing investments in aerospace (SpaceX) and artificial intelligence (Shield AI)..

/PRNewswire/ -- 致力于高增长创新的Jetstream风险基金宣布投资Wonderlab Bio，这是一家现成细胞疗法的先驱企业，进一步扩大了普通投资者获取顶级风险投资机会的渠道。这项战略性投资彰显了Jetstream支持跨领域变革性技术的决心，将Wonderlab Bio突破性的再生医学与其在航空航天（SpaceX）和人工智能（Shield AI）等领域的现有投资并列。

Revolutionizing Cell Therapy

革新细胞治疗

Based in Boston, Wonderlab Bio is addressing a massive gap in regenerative medicine. Current cell therapies are patient-specific, cost between $50,000 and $500,000, and often trigger immune rejection—limiting their use to life-threatening conditions.

总部位于波士顿的 Wonderlab Bio 正在解决再生医学中的一个巨大缺口。当前的细胞疗法针对患者个体定制，费用在 5 万到 50 万美元之间，并且常常引发免疫排斥反应，因此其应用仅限于危及生命的情况。

Wonderlab Bio engineers living cells into accessible medicines using a proprietary bank of iPSCs (induced pluripotent stem cells) sourced from HLA-homozygous 'super donors'. Because these donors' immune profiles match broad patient populations, the therapies are naturally accepted by the body without the need for systemic immunosuppression..

Wonderlab生物公司利用来自HLA纯合子“超级供体”的专有iPSC（诱导多能干细胞）库，将活细胞转化为可及的药物。由于这些供体的免疫特征与广泛的患者群体相匹配，因此这些疗法能够被身体自然接受，而无需系统性免疫抑制。

'Wonderlab's approach to HLA-matching is a complete paradigm shift for treating chronic conditions,' said Chris Yoo, Portfolio Manager at Jetstream. 'By removing the need for immunosuppression and drastically lowering manufacturing costs, they are unlocking the potential of cell therapy for tens of millions of patients who currently have no regenerative options.'.

“Wonderlab的HLA匹配方法为治疗慢性疾病带来了彻底的范式转变，”Jetstream的投资组合经理Chris Yoo表示。“通过消除对免疫抑制的需求并大幅降低制造成本，他们正在释放细胞疗法的潜力，使数千万目前没有再生选择的患者受益。”

Targeting Osteoarthritis and Beyond

针对骨关节炎及更多领域

Wonderlab Bio's lead program focuses on knee osteoarthritis, a condition affecting 32.5 million Americans and currently lacking any FDA-approved cell therapy. Their injectable, iPSC-derived chondrocyte therapy targets cartilage regeneration without surgery, at a projected price point below the cost of a traditional joint replacement..

Wonderlab Bio的主导项目专注于膝关节骨性关节炎，这是一种影响3250万美国人的疾病，目前尚无任何FDA批准的细胞疗法。其可注射的、由iPSC衍生的软骨细胞疗法旨在无需手术的情况下实现软骨再生，预计价格低于传统关节置换手术的费用。

The company's platform is already demonstrating significant traction, backed by preclinical animal studies showing cartilage repair and inclusion in a $42 million ARPA-H federal program supporting regenerative medicine. Wonderlab's super donor bank currently covers over 90% of the U.S. population, laying the groundwork for future applications in cardiac disease and neurodegeneration..

该公司的平台已经展现出显著的吸引力，得到了临床前动物研究的支持，这些研究显示了软骨修复的效果，并且被纳入了一个支持再生医学的4200万美元的ARPA-H联邦计划。Wonderlab的超级供体库目前已覆盖美国90%以上的人口，为未来在心脏病和神经退行性疾病领域的应用奠定了基础。

About Jetstream Venture Fund

关于Jetstream风险基金

Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, seeking to provide investors access to high-growth companies with lower minimums and no carried interest. Visit

Jetstream风险基金是由Xcellerant Ventures和Sweater Industries LLC管理的区间基金，旨在为投资者提供以较低门槛投资高增长公司且不收取附带权益的机会。访问

https://www.jvf.vc

https://www.jvf.vc

.

。

Disclosure: Investors should carefully consider the investment objectives, risks, charges, and expenses before investing. The prospectus contains this information and can be obtained by visiting

披露：投资者在投资前应仔细考虑投资目标、风险、费用和开支。招股说明书包含此信息，可以通过访问获取。

https://www.jvf.vc

https://www.jvf.vc

. Please read carefully before investing.

请在投资前仔细阅读。

Media contact: Dawson Fearnow,

媒体联系人：道森·费尔诺，

[email protected]

电子邮件地址

SOURCE Jetstream Venture Fund

来源：Jetstream 风险投资基金

21

21

%

%

more press release views with

更多新闻发布视图

Request a Demo

请求演示